Active Ingredient History
Duvelisib (IPI-145), is an orally available, small-molecule, selective dual inhibitor of phosphatidylinositol 3 kinase (PI3K) δ and γ isoforms originated by Intellikine (owned by Takeda) and developed by Infinity Pharmaceuticals. Orally administered duvelisib was rapidly absorbed, with a dose-proportional increase in exposure. The compound produced a half-life of approximately 7-12 hours, following 14 days of dosing. Duvelisib exerts profound effects on adaptive and innate immunity by inhibiting B and T cell proliferation, blocking neutrophil migration, and inhibiting basophil activation. Duvelisib blockade of PI3K-δ and PI3K-γ potentially lead to significant therapeutic effects in multiple inflammatory, autoimmune, and hematologic diseases. The molecule is in phase III development as a combination therapy for patients with haematological malignancies such as chronic lymphocytic leukemia and follicular lymphoma. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Leukemia, Lymphocytic, Chronic, B-Cell (approved 2018)
Lymphoma, Follicular (approved 2018)
Arthritis, Rheumatoid (Phase 2)
Asthma (Phase 2)
COVID-19 (Phase 2)
Enteropathy-Associated T-Cell Lymphoma (Phase 2)
Healthy Volunteers (Phase 1)
Hematologic Neoplasms (Phase 2)
Hodgkin Disease (Phase 1)
Intestinal Neoplasms (Phase 2)
Leukemia (Phase 2)
Leukemia, Large Granular Lymphocytic (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Leukemia, Lymphoid (Phase 1)
Leukemia-Lymphoma, Adult T-Cell (Phase 1)
Leukemia, Prolymphocytic, T-Cell (Phase 1)
Liver Diseases (Phase 1)
Lymphoma (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 3)
Lymphoma, Extranodal NK-T-Cell (Phase 1)
Lymphoma, Follicular (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 2)
Melanoma (Phase 1/Phase 2)
Multiple Myeloma (Phase 1)
Neoplasms (Phase 1/Phase 2)
Sezary Syndrome (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue